 - Must not have received systemic antineoplastic therapy including radiation therapy within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction. Patients may also have received all-trans retinoic acid ATRA if there is an early suspicion of acute promyelocytic leukemia APL, M3-AML, although if confirmed to have APL these patients will be excluded from the study. 